Hepatocellular Carcinoma- Pipeline Insight, 2022
Description
Hepatocellular Carcinoma- Pipeline Insight, 2022
DelveInsight’s, “Hepatocellular Carcinoma- Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hepatocellular Carcinoma: Overview
Hepatocellular carcinoma (HCC) is a rare disorder in the United States, but the most common primary tumor of the liver. Most people have an underlying liver disease such as infection with hepatitis B or C virus, or non-alcoholic fatty liver disease. Most people have cirrhosis, which is scarring of the liver that can occur as a result of chronic liver diseases. If HCC is found early, there may be curative treatments offered. However, HCC often does not cause any symptoms, especially early in the disease course. If HCC is diagnosed at a late stage, patients may not be able to receive curative treatments, and care is then geared toward helping people have a better quality of life. Although HCC does not necessarily cause symptoms, many individuals will have symptoms caused by the underlying liver disease. The exact cause of HCC is not fully understood. Most people do not have any noticeable symptoms associated with hepatocellular carcinoma. They may have symptoms related liver cirrhosis that may become more difficult to control. Because of the underlying liver disease and HCC, the liver may become decompensated. This means that an organ, in this instance the liver, is having trouble compensating for the effects of disease. Symptoms of liver decompensation can include fluid buildup in the abdomen (ascites), an abnormally enlarged spleen (splenomegaly), high pressure in the main vein that supplies the liver (portal hypertension), yellowing of the skin, eyes and mucous membranes because of the buildup of bile in the body (jaundice), and hepatic encephalopathy, a condition in which toxins that are normally cleared by the liver are not cleared and instead travel through the bloodstream to the brain. Although HCC often does not cause symptoms, some people will develop mild to moderate pain in the upper abdomen and may feel full despite eating less food than usual (early satiety). Some may experience fatigue, unintended weight loss or have a mass that can be felt (palpable) in the upper abdomen. Less commonly, fever or diarrhea may be present. Usually, such symptoms occur later in the diseases course and indicate advanced disease. The exact reasons why hepatocellular carcinoma develops is not fully understood. It is a multifactorial disorder, which means that there are multiple factors that must occur before the disorder develops. There are risk factors that increase the chances of a person developing HCC. Most people have an underlying liver disorder including infection with hepatitis B or C viruses, scarring of the liver (cirrhosis), a condition in which fat builds up in the liver (non-alcoholic fatty liver disease), and a condition in which fat builds up in the liver along with inflammation and liver cell damage (nonalcoholic steatohepatitis or NASH). Heavy drinking is also a risk factor for HCC; excessive drinking is one of the main causes of cirrhosis and can also cause alcoholic fatty liver disease. Cigarette smoking is also a potential risk factor for HCC. Obesity and diabetes are modest risk factors, but the absolute risk is considered to be very low. Foods contaminated with aflatoxin also increase the risk of HCC; this is even true for people without an underlying liver disorder.
“Hepatocellular Carcinoma- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatocellular Carcinoma pipeline landscape is provided which includes the disease overview and Hepatocellular Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Hepatocellular Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Hepatocellular Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatocellular Carcinoma Emerging Drugs
Further product details are provided in the report……..
Hepatocellular Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Hepatocellular Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 80+ products under different phases of clinical development like
Hepatocellular Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatocellular Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatocellular Carcinoma drugs.
Hepatocellular Carcinoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Hepatocellular Carcinoma- Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hepatocellular Carcinoma: Overview
Hepatocellular carcinoma (HCC) is a rare disorder in the United States, but the most common primary tumor of the liver. Most people have an underlying liver disease such as infection with hepatitis B or C virus, or non-alcoholic fatty liver disease. Most people have cirrhosis, which is scarring of the liver that can occur as a result of chronic liver diseases. If HCC is found early, there may be curative treatments offered. However, HCC often does not cause any symptoms, especially early in the disease course. If HCC is diagnosed at a late stage, patients may not be able to receive curative treatments, and care is then geared toward helping people have a better quality of life. Although HCC does not necessarily cause symptoms, many individuals will have symptoms caused by the underlying liver disease. The exact cause of HCC is not fully understood. Most people do not have any noticeable symptoms associated with hepatocellular carcinoma. They may have symptoms related liver cirrhosis that may become more difficult to control. Because of the underlying liver disease and HCC, the liver may become decompensated. This means that an organ, in this instance the liver, is having trouble compensating for the effects of disease. Symptoms of liver decompensation can include fluid buildup in the abdomen (ascites), an abnormally enlarged spleen (splenomegaly), high pressure in the main vein that supplies the liver (portal hypertension), yellowing of the skin, eyes and mucous membranes because of the buildup of bile in the body (jaundice), and hepatic encephalopathy, a condition in which toxins that are normally cleared by the liver are not cleared and instead travel through the bloodstream to the brain. Although HCC often does not cause symptoms, some people will develop mild to moderate pain in the upper abdomen and may feel full despite eating less food than usual (early satiety). Some may experience fatigue, unintended weight loss or have a mass that can be felt (palpable) in the upper abdomen. Less commonly, fever or diarrhea may be present. Usually, such symptoms occur later in the diseases course and indicate advanced disease. The exact reasons why hepatocellular carcinoma develops is not fully understood. It is a multifactorial disorder, which means that there are multiple factors that must occur before the disorder develops. There are risk factors that increase the chances of a person developing HCC. Most people have an underlying liver disorder including infection with hepatitis B or C viruses, scarring of the liver (cirrhosis), a condition in which fat builds up in the liver (non-alcoholic fatty liver disease), and a condition in which fat builds up in the liver along with inflammation and liver cell damage (nonalcoholic steatohepatitis or NASH). Heavy drinking is also a risk factor for HCC; excessive drinking is one of the main causes of cirrhosis and can also cause alcoholic fatty liver disease. Cigarette smoking is also a potential risk factor for HCC. Obesity and diabetes are modest risk factors, but the absolute risk is considered to be very low. Foods contaminated with aflatoxin also increase the risk of HCC; this is even true for people without an underlying liver disorder.
“Hepatocellular Carcinoma- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatocellular Carcinoma pipeline landscape is provided which includes the disease overview and Hepatocellular Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Hepatocellular Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hepatocellular Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Hepatocellular Carcinoma.
This segment of the Hepatocellular Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatocellular Carcinoma Emerging Drugs
- Tivozanib: AVEO Oncology
- SCT-I10A: Sinocelltech
Further product details are provided in the report……..
Hepatocellular Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Hepatocellular Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hepatocellular Carcinoma
Phases
DelveInsight’s report covers around 80+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Hepatocellular Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatocellular Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatocellular Carcinoma drugs.
Hepatocellular Carcinoma Report Insights
- Hepatocellular Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hepatocellular Carcinoma drugs?
- How many Hepatocellular Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatocellular Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatocellular Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hepatocellular Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sinocelltech
- AVEO Oncology
- Oxford BioTherapeutics
- Beijing SyngenTech
- Surface Oncology
- Novartis Oncology
- Array BioPharma
- Taizhou Hanzhong Pharmaceuticals
- Akeso Biopharma
- Innovent Biologics
- Eli Lilly and Company
- Shanghai Henlius Biotech
- Chugai Pharmaceutical
- CStone Pharmaceuticals
- Jiangsu Hengrui Medicine
- Shenogen Pharma
- Tivozanib
- SCT-I10A
- OBT-624
- SynOV1.1
- SRF388
- INC280
- HX008
- AK104
- IBI318
- Serplulimab
- ERY974
- Fisogatinib
- SHR 1210
- Icaritin
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
250 Pages
- Introduction
- Executive Summary
- Hepatocellular Carcinoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Last Stage Products (Phase II/ III)
- Comparative Analysis
- SCT-I10A: Sinocelltech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Hepatocellular Carcinoma Key Companies
- Hepatocellular Carcinoma Key Products
- Hepatocellular Carcinoma - Unmet Needs
- Hepatocellular Carcinoma - Market Drivers and Barriers
- Hepatocellular Carcinoma - Future Perspectives and Conclusion
- Hepatocellular Carcinoma Analyst Views
- Hepatocellular Carcinoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
